A study consisting of 48 pediatric SLE patients and 67 healthy controls demonstrated that serum IFN-α2 levels are strongly positively correlated with the IFN-I gene signature and that serum IFN-α2 levels are significantly associated with both the safety of estrogens according to the Lupus Erythematosus National Assessment-SLE disease activity index (SLEDAI) and the British Isles Lupus Assessment Group 2004, while the IFN-I gene signature did not show this association [106]. Here, IFNA2 is linked to systemic lupus erythematosus.